Sign In
Buy VERU
$2.77
+0.440 (+18.88%)
At Close: Aug 10, 2026
Veru to Participate in the Virtual BTIG Obesity Health Forum
08:30am, Wednesday, 11'th Jun 2025
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic a
--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial
Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom
09:36pm, Monday, 26'th May 2025
Veru Inc. has pivoted to focus on preventing lean mass reduction in patients using GLP-1 agonists, leveraging its lead asset, enobosarm. A Phase 2b trial showed that a 3mg dose of Enobosarm reduces le
Veru Inc. (VERU) Q2 2025 Earnings Call Transcript
12:42pm, Thursday, 08'th May 2025
Veru Inc. (NASDAQ:VERU ) Q2 2025 Results Conference Call May 8, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications Mitchell Steiner -
Moderated discussion with preeminent obesity expert Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D.
Veru Participates in a Virtual Investor KOL Connect Segment
09:25am, Thursday, 08'th May 2025
-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE)
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress
06:30am, Thursday, 08'th May 2025
--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the secon
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8
08:30am, Thursday, 01'st May 2025
MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and in
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit
08:30am, Wednesday, 16'th Apr 2025
MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
08:30am, Monday, 31'st Mar 2025
MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic
Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround
10:35am, Thursday, 06'th Mar 2025
The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in re
Veru Inc (VERU) Q1 2025 Earnings Call Transcript
02:35pm, Thursday, 13'th Feb 2025
Veru Inc (NASDAQ:VERU ) Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Sam Fisch - Executive Director, Investor Relations and Corporate Communications. Mitchell Ste
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
06:30am, Thursday, 13'th Feb 2025
--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as great
Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough
10:34am, Monday, 27'th Jan 2025
Veru Inc. VERU stock is plummeting on Monday after the company released topline results from the Phase 2b QUALITY clinical study of enobosarm for weight reduction.
-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on averag
